Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Sarepta Therapeutics (SRPT)

Sarepta reports preliminary 2025 net product revenue of $1.86 billion

Mixed Impact 3 of 5 earnings Written later

Sarepta gave preliminary, unaudited fourth-quarter and full-year 2025 results at the J.P. Morgan Healthcare Conference, reporting $369.6 million in fourth-quarter net product revenue and $1.86 billion for the year. The company reconfirmed a yearly ELEVIDYS sales floor of $500.0 million but said it will not provide more detailed 2026 guidance until it evaluates its initiatives. Final results are due in late February 2026 and may differ materially from these figures.

Key points

  • Full-year 2025 total net product revenue of $1.86 billion; fourth quarter $369.6 million
  • ELEVIDYS fourth-quarter net product revenue of $110.4 million, affected by a severe flu season and rescheduling of 6 patient infusions into 2026
  • PMO net product revenue of $259.2 million in the fourth quarter and $965.6 million for the full year
  • Year-end 2025 cash, cash equivalents, restricted cash and investments of approximately $953.8 million; final results expected in late February 2026

The filing

CompanySarepta Therapeutics (SRPT)
Form8-K, current report
Filed with the SECJan 12, 2026, 12:05 PM ET
Accession number0001193125-26-010116

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.